Prognostic value of CD73 expression in resected colorectal cancer liver metastasis.
CD73-Adenosine pathway
biomarker
colorectal cancer
immune checkpoint
liver metastasis
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
07
2019
revised:
27
10
2019
accepted:
19
12
2019
entrez:
5
5
2020
pubmed:
5
5
2020
medline:
5
5
2020
Statut:
epublish
Résumé
Immune checkpoint blockade has not yet been effective in patients with mismatch repair proficient metastatic colorectal cancer. Targeting immunosuppressive metabolic pathways is being explored as a new immunotherapeutic approach. We assessed whether CD73, the rate limiting enzyme that catalyzes the degradation of extracellular AMP into immunosuppressive adenosine, could be an immunological determinant of colorectal liver metastases (CRLMs). By immunofluorescence on tissue microarrays, intratumoral CD73 expression (tCD73) was analyzed in 391 CRLMs resected in 215 patients, and soluble CD73 (sCD73) was measured by ELISA in the pre-operative serum of 193 patients. High tCD73 was associated with worse pathological features, such as multiple and larger CRLMs, and poorer pathologic response to pre-operative chemotherapy. The median time to recurrence and disease-specific survival after CRLM resection was significantly shorter in patients with high tCD73 (11.0 and 46.4 months, respectively) compared with low tCD73 (19.0 and 61.5 months, respectively). tCD73 was strongly associated with patient outcomes independently of clinicopathological variables. sCD73 did not correlate with tCD73. Patients with high levels of sCD73 also had shorter disease-specific survival. Our results suggested that CD73 in CRLMs may be prognostically informative and may help select patients more likely to respond to adenosine pathway blocking agents.
Identifiants
pubmed: 32363113
doi: 10.1080/2162402X.2020.1746138
pii: 1746138
pmc: PMC7185220
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1746138Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
J Surg Oncol. 2012 Aug 1;106(2):130-7
pubmed: 22287455
Clin Cancer Res. 2014 Jan 15;20(2):331-43
pubmed: 24218514
J Transl Med. 2017 Dec 4;15(1):244
pubmed: 29202855
Science. 2015 Dec 11;350(6266):1387-90
pubmed: 26516200
Oncogene. 2010 Sep 30;29(39):5346-58
pubmed: 20661219
Ann Oncol. 2007 Feb;18(2):299-304
pubmed: 17060484
Histopathology. 2007 Jan;50(1):113-30
pubmed: 17204026
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
J Immunol. 2009 Nov 1;183(9):5487-93
pubmed: 19843934
Cancer Res. 2017 Oct 15;77(20):5652-5663
pubmed: 28855210
Clin Cancer Res. 2004 Nov 1;10(21):7252-9
pubmed: 15534099
Ann Oncol. 2018 Apr 1;29(4):1056-1062
pubmed: 29145561
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Chembiochem. 2012 Nov 5;13(16):2384-91
pubmed: 22997138
Oncoimmunology. 2016 Jan 19;5(5):e1127496
pubmed: 27467942
Tumour Biol. 2015 Jul;36(7):5459-66
pubmed: 25677906
Cell. 2018 Oct 18;175(3):751-765.e16
pubmed: 30318143
Clin Cancer Res. 2016 Jan 1;22(1):158-66
pubmed: 26253870
Nat Rev Cancer. 2017 Dec;17(12):709-724
pubmed: 29059149
Cancer Immunol Res. 2014 Jun;2(6):530-7
pubmed: 24894090
Immunol Lett. 2019 Jan;205:31-39
pubmed: 29758241
Oncotarget. 2017 Apr 6;8(34):57327-57336
pubmed: 28915673
Oncoimmunology. 2012 Mar 1;1(2):217-218
pubmed: 22720247
Appl Immunohistochem Mol Morphol. 2019 Aug;27(7):558-563
pubmed: 29271792
Med Oncol. 2000 Nov;17(4):319-24
pubmed: 11114712
Biochim Biophys Acta. 2008 May;1783(5):673-94
pubmed: 18302942
Blood. 2008 Jan 1;111(1):251-9
pubmed: 17909080
J Natl Cancer Inst. 2018 Jan 1;110(1):
pubmed: 28922789
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Cancer Res. 2012 May 1;72(9):2190-6
pubmed: 22396496
PLoS One. 2016 Oct 12;11(10):e0164420
pubmed: 27732656
Nat Rev Drug Discov. 2008 Sep;7(9):759-70
pubmed: 18758473
Trends Mol Med. 2013 Jun;19(6):355-67
pubmed: 23601906